news
Will novel antibiotic become front-line for C. difficile?
Based on positive Phase II data, the first-in-class antibiotic candidate ibezapolstat for C. difficile is expected to advance to Phase III trials more quickly.
List view / Grid view
C. Difficile
news
Safety analysis published for C. diff biotherapeutic
The largest safety evaluation of any microbiota-based live biotherapeutic includes data for up to two years for the first approved microbiome-based treatment for recurrent Clostridioides difficile (C. diff).
article
Microbiome therapeutic development boosted by metabolomics
There is a growing adoption of metabolomics to support drug discovery and development. Metabolomics involves the comprehensive analysis of metabolites in biological specimens. As such, it is commonly used for the discovery and validation of biomarkers that can support critical decisions in the drug development process. In this article, Christopher…
news
Antibiotic therapy for nearly 1 in 4 adults with pneumonia does not work
22 May 2017 | By Niamh Marriott, Junior Editor
Approximately one in four adults prescribed an antibiotic in an outpatient setting for community-acquired pneumonia does not respond to treatment...
news
FDA grants QIDP for C. Difficile IV treatment
25 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Morphochem announced today that the U.S. FDA has designated Morphochem’s intravenous antibacterial product as a Qualified Infectious Disease Product...
